Univerzitna nemocnica L. Pasteura Kosice
- Address
- lock Available on a paid plan
Univerzitna nemocnica L. Pasteura Kosice - Advanced Clinical Research Center
Univerzitna nemocnica L. Pasteura Kosice is a distinguished clinical research institution conducting comprehensive trials across multiple therapeutic areas. The center demonstrates particular expertise in neurodegenerative diseases, dermatological conditions, and hematologic malignancies, with a strong focus on innovative therapeutic approaches for complex medical conditions.
- Alzheimer's Disease and Related Psychosis: Multiple Phase 3 trials investigating novel treatments for cognitive decline, psychosis associated with Alzheimer's disease, and mild cognitive impairment
- Hidradenitis Suppurativa: Advanced research in moderate to severe cases using biologic therapies including sonelokimab, secukinumab, and lutikizumab
- Hematologic Malignancies: Studies in chronic myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma
- Autoimmune and Inflammatory Disorders: Clinical trials for multiple sclerosis, cutaneous lupus erythematosus, atopic dermatitis, and chronic spontaneous urticaria
The research center also maintains active programs in psychiatric disorders including major depressive disorder and schizophrenia, as well as rare conditions such as ataxia-telangiectasia and fetal and neonatal alloimmune thrombocytopenia. Additional focus areas include renal diseases (IgA nephropathy, FSGS/minimal change disease), metabolic liver disease (NASH), and acute conditions such as severe viral lung infections, reflecting a comprehensive approach to advancing medical knowledge across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 59 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 59 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1Novartis Pharma AG3active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG9trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Univerzitna nemocnica L. Pasteura Kosice
lock Showing 1 of 38 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 59 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 4 | Unknown | 2021-03-29 | 2024-04-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.